(Albany, United States) As per DelveInsight’s assessment, globally, the Radiodermatitis pipeline constitutes 3+ key companies continuously working towards developing 3+ Radiodermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Radiodermatitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Radiodermatitis clinical trials studies, Radiodermatitis NDA approvals (if any), and product development activities comprising the technology, Radiodermatitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Radiodermatitis pipeline treatment landscape of the report, click here @ Radiodermatitis Pipeline Outlook

 

Key Takeaways from the Radiodermatitis Pipeline Report

• DelveInsight’s Radiodermatitis Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading Radiodermatitis Companies working in the market include Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical, and others.
• Promising Radiodermatitis Pipeline Therapies in the various stages of development include DermoRelizema cream, Dexeryl, LUT014 Gel, Calendula, Aquaphor, StrataXRT, Sorbolene, APN201, Omaveloxolone Lotion 0.5%, and others
• On March 2023, Relife Italia S.r.l. announced a study of phase x clinical trials for DermoRelizema cream and Dexeryl. This is a post marketing, interventional, randomized, single-center, prospective, controlled study, for the evaluation of the clinical performance and tolerability of a cream-based medical device (DermoRelizemaTM cream) in the management care of radiodermatitis in women with breast cancer. Assessments and evaluations will be performed by a physician in a blind fashion.
• On May 2023, Stratpharma AG announced a study of phase x clinical trials for Calendula and Aquaphor. Routinely collected data on radiation-induced skin toxicity from 2010 to 2022 will be retrospectively analyzed. Data will be split into two cohorts: patients that received 1) StrataXRT and 2) standard of care. The incidence of grade ≥ 2 radiation dermatitis, the time to onset of grade ≥ 2 radiation dermatitis, the radiation dose at onset of grade ≥ 2 radiation dermatitis, the incidence of moist desquamation and the number of treatment interruptions will be compared between the cohorts.
• On May 2023, Reata Pharmaceuticals Inc announced a study of phase 2 clinical trials for Omaveloxolone Lotion 0.5%, Vehicle Lotion, 3D conformal radiation therapy. This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.

 

Radiodermatitis Overview

Radiation dermatitis is a side effect of external beam ionizing radiation. It is also known as radiodermatitis, x-ray dermatitis, radiation skin damage or a radiation burn. Most commonly, radiation-induced dermatitis is caused by radiotherapy for underlying malignancies.

 

To explore more information on the latest breakthroughs in the Radiodermatitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Radiodermatitis Emerging Drugs Profile

• TEMPOL: Matrix Biomed
• LUT 014: Lutris Pharma

 

Radiodermatitis Pipeline Therapeutics Assessment

There are approx. 3+ Radiodermatitis companies which are developing the therapies for Radiodermatitis. The Radiodermatitis companies which have their Radiodermatitis drug candidates in the mid to advanced stage, i.e. Phase II include, Matrix Biomed and others.

 

Request a sample and discover the recent advances in Radiodermatitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Radiodermatitis Drugs and Companies

• LUT014 Gel: Lutris Pharma Ltd.
• Calendula: Stratpharma AG
• APN201: Apeiron Biologics

 

Radiodermatitis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Radiodermatitis Therapeutics Market include-

Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical, and others.

 

Dive deep into rich insights for drugs for Radiodermatitis Pipeline, click here for Radiodermatitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Scope of the Radiodermatitis Pipeline Report

• Coverage- Global
• Radiodermatitis Companies- Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical, and others.
• Radiodermatitis Pipeline Therapies- DermoRelizema cream, Dexeryl, LUT014 Gel, Calendula, Aquaphor, StrataXRT, Sorbolene, APN201, Omaveloxolone Lotion 0.5%, and others
• Radiodermatitis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Radiodermatitis Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Table of Content

1. Introduction
2. Radiodermatitis Executive Summary
3. Radiodermatitis: Overview
4. Radiodermatitis Pipeline Therapeutics
5. Radiodermatitis Therapeutic Assessment
6. Radiodermatitis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Radiodermatitis Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. TEMPOL: Matrix Biomed
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Radiodermatitis Key Companies
20. Radiodermatitis Key Products
21. Radiodermatitis- Unmet Needs
22. Radiodermatitis- Market Drivers and Barriers
23. Radiodermatitis- Future Perspectives and Conclusion
24. Radiodermatitis Analyst Views
25. Radiodermatitis Key Companies
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services